Alexandria — Full Portfolio

Boundless Bio develops precision oncology medicines targeting ecDNA-amplified cancers, specifically creating a new category of ecDNA-directed therapies for patients with oncogenic alterations.

BiotechMedical DevicesLa Jolla, US

ZDZachary D. Hornby(Executive Officer, Director)inRDRobert Doebele(Chief Medical Officer)inChristian Hassig(Chief Scientific Officer)JOJessica Oien(Chief Legal Officer and Corporate Secretary)in

BoardBenjamin Cravatt, Ph.D.(Director)KBKristina Burow(Director)in

Co-investorsARARCH Venture PartnersNENextech InvestRARA CapitalWEWellington ManagementCICity Hill VenturesSESectoral Asset Management+3 more

Disc Medicine is a biopharmaceutical company developing therapies from discovery through clinical development for patients in need.

BiotechHealthtech

JQJohn Quisel(Chief Executive Officer)inJFJean Franchi(Chief Financial Officer)inJYJonathan Yu(Chief Operating Officer)inWSWill Savage(Chief Medical Officer)inPSPamela Stephenson(Chief Commercial Officer)inSCSteve Caffé(Chief Regulatory Officer)in

Co-investorsACAccess BiotechnologyATAtlas VentureBABain Capital Life SciencesFOForesite CapitalFRFrazier Life SciencesOROrbiMed+7 more

Imara is a clinical-stage biopharmaceutical company developing small molecule therapeutics for unmet medical needs, currently advancing ELVN-001, a selective kinase inhibitor designed to treat chronic myeloid leukemia by targeting the BCR-ABL gene fusion.

BiotechCambridge, US

JGJames G. McArthur(Executive Officer, Director)Christoph M. Adams(Executive Officer, Director)Richard Fair(President, Chief Executive Officer, Director)

BoardSara Nayeem(Director)Barbara Dalton(Director)David Mott(Director)

Co-investorsBABay City CapitalNENew Enterprise Associates (NEA)PFPfizer Venture InvestmentsRARA CapitalARArix BioscienceJMJMI Equity+3 more

Korro Bio is a biotechnology company developing a new class of RNA-editing therapies guided by human genetics and disease biology.

BiotechHealthtechCambridge, US

NBNessan Bermingham(Mr. Bermingham is the Executive Chair of the Issuer.)inJFJean-François Formela(Director)inOCOmmer Chohan(Mr. Chohan is the Secretary and Treasurer of the Issuer.)inRARam Aiyar(Chief Executive Officer, President and Director)inTCTodd Chappell(Chief Operating Officer)in

Co-investorsATAtlas VentureMCMC Healthcare VenturesNENew Enterprise Associates (NEA)QIQiming Venture PartnersQIQiming Venture Partners USARORock Springs Capital+3 more

Maze Therapeutics develops precision medicines for common diseases with high unmet need, using its Compass platform based on human genetics and variant functionalization.

AI & Machine LearningBiotechSouth San Francisco, US

CHCharles Homcy(Director)JCJason Coloma(Chief Executive Officer)in

Co-investorsANAndreessen HorowitzARARCH Venture PartnersFOForesite CapitalFRFrazier Life SciencesGVGV (Google Ventures)HEHercules Capital, Inc.+9 more

Neumora is a clinical research company developing investigational medications, with a focus on conducting clinical trials to obtain regulatory approval and make treatments available to patients.

BiotechDeep TechDigital HealthMedical DevicesWatertown, US

PLPaul L. Berns(Chairman and Chief Executive Officer)Joshua Pinto(Executive Officer)TTTamara Tompkins(Executive Officer)inKari Stefansson(Director)MHMaykin Ho(Director)AHAlaa Halawa(Director)

Co-investorsARARCH Venture PartnersCACatalio Capital Management, LPF-F-Prime CapitalK2K2 HealthVenturesMEMercury FundPRPremier Partners+12 more

Senti Bio develops cell and gene therapies for cancer and difficult-to-treat diseases using synthetic biology and engineered Gene Circuits to enhance precision, control, and selectivity in targeting tumor cells.

BiotechDeep TechMedical DevicesSouth San Francisco, US

TLTim Lu(Co-Founder and Chief Executive Officer)inPLPhilip Lee(Executive Officer)inKanya Rajangam(President, Head of Research & Development and Chief Medical Officer)inYLYvonne Li(Executive Officer)inJames Collins(Director)Timothy Lu(Founder)

Co-investorsEVEvolution VC PartnersFLFlucas VenturesGAGaingelsGRGreen Sands EquityLILifeforce CapitalLILifeSci Venture Partners+13 more

Congruence is a drug discovery company that applies protein dynamics, biophysics, machine learning, and computational chemistry to model proteins in their full dynamic state and predict disease correction in silico.

AI & Machine LearningBiotechDeep Tech

CDClarissa Desjardins(Founder)in

Co-investorsOROrbiMedDIDIMENSIONANAngelini VenturesBDBDC Thrive Venture Fund for WomenLULumira VenturesAMAmplitude Venture Capital+1 more

Thryv Therapeutics is a clinical-stage biotechnology company developing selective inhibitors of serum glucocorticoid inducible kinase 1 (SGK1) for inherited cardiac arrhythmias such as Long QT Syndrome and acquired cardiometabolic diseases.

BiotechHealthtechMedical Devices

PFPaul F. Truex(Chairman of the Board & Chief Executive Officer)inDebra OdinkinASAmy Sehnertin

Co-investorsAMAmzak HealthADadMare BioInnovationsCTCTI Life Sciences Fund L.P.LULumira Ventures

Applied Therapeutics is a biopharmaceutical company developing novel drugs for rare diseases with high unmet medical need.

BiotechHealthtechNew York, US

SSShoshana Shendelman(Executive Officer, Director)in

BoardLes Funtleyder(Director)

Board seatJoel Marcus· per SEC Form D · $20M raise · filed Nov 2019

Co-investorsEVEvolution VC PartnersVEVenrock Healthcare Capital Partners

Ability is a biotechnology company developing highly-selective, immune cell-modulating antibody therapeutics for patients with inflammatory diseases and cancer.

AI & Machine LearningBiotechHealthtechMontreal, CA

GDGiles Day(Co-founder)in

Co-investorsPAPage One VenturesFOFonds de solidarité FTQ

Ability.ai builds AI agents that automate repetitive, rule-based workflows across business functions like customer support, HR, marketing, sales, finance, and IT, which customers deploy on their own platform called Trinity.

AI & Machine LearningDeveloper ToolsEnterprise SoftwareSaaSSales TechSan Francisco, US

EVEugene Vyborov(Founder and CEO)in

Co-investorsSISID Venture Partners191991 VenturesFOFonds de solidarité FTQ

AeroRx is a clinical-stage biopharmaceutical company developing nebulized fixed-dose combination therapies (LABA/LAMA and triple LABA/LAMA/ICS) for moderate-to-severe COPD patients who are underserved by inhalers.

BiotechHealthtechLa Jolla, US

Ahmet Tutuncu(CEO and Co-founder)inAhmet Tutuncu, M.D., Ph.D.(Executive Officer, Director)

BoardTRTighe Reardon(Executive Officer)Heather Preston, M.D.(Director)Jay B. Lichter, Ph.D.(Director)Sanford Madigan, Ph.D.(Director)

Co-investorsAVAvalon BioVenturesCOCorrelation Ventures

ARTBIO develops alpha radioligand therapies (ARTs) for cancer treatment, designing target-and-molecule combinations intended to kill tumors while sparing healthy tissue.

BiotechHealthtechMedical DevicesOslo, NO

RLRoy Larsen(Scientific Co-Founder)Øyvind Bruland(Scientific Co-Founder; SAB Chairman)Margaret Yu(Chief Medical Officer)inPhilippe Dasse(Chief Technical Officer)inADAmra Demirovic(Chief Human Resources Officer)inNHNicole Hadas(Chief Legal Officer)

Co-investorsB B Capital GroupB4B4 CapitalF-F-Prime CapitalSOSofinnova VenturesB B CapitalOMOmega Funds+2 more

Asher Bio develops selective immunotherapy drugs that target specific immune cell types to promote beneficial effects while minimizing toxicity.

BiotechHealthtechMedical DevicesSan Francisco, US

IDIvana Djuretic(Founder)inAYAndy Yeung(Drug discovery)inYik Andy Yeung(Executive Officer, Director, Promoter)

Co-investorsEMEmles Venture PartnersGOGoAhead VenturesMIMission Bay CapitalMIMission BiocapitalRARA CapitalWEWellington Management+9 more

Aspen Neuroscience develops iPSC-derived autologous cell therapies for neurological diseases, with a lead product (ANPD001) in Phase 1/2a clinical trials for Parkinson's disease.

BiotechDeep TechDigital HealthMedical DevicesSan Diego, US

ABAndrés Bratt-Leal(Co-Founder and Senior Vice President, Research & Development)inABANDRÉS BRATT-LEAL, Ph.D.(Co-Founder; Senior Vice President, Research & Development)DMDamien McDevitt(President and Chief Executive Officer)inDMDAMIEN MCDEVITT, Ph.D.(President and Chief Executive Officer)

Co-investorsARARCH Venture PartnersLILifeforce CapitalOROrbiMedDODomain AssociatesEDEDB InvestmentsSESection 32+10 more

Clinical-stage drug-device company developing pegloprastide (AVB-620) for real-time surgical margin detection in cancer surgery.

Co-investorsTOTorrey Pines Investment

Bear Flag Robotics developed autonomous technology for farming before being acquired by John Deere in 2021.

Advanced ManufacturingAgTechRoboticsNew York City, US

ICIgino Cafiero(CEO)inADAubrey Donnellan(Founder)inIgino Cafiero Aubrey Donnellan(Founder)Andrew Deal(Senior Software Engineer)Keith Swett(Senior Software Engineer)Dave Bertucci(Senior System Engineer)

Co-investorsAGAgFunderEXExpansion Venture CapitalGRGraphene VenturesGRGreen Cow Venture CapitalINIndustrious VenturesLILiquid Ventures+12 more

Confluence Genetics (operating at bensonhillbio.com) is a seed innovation company that develops soybean genetics using AI-driven plant science and proprietary tools such as eMERGE Genetics and CropOS.

Durham, US

Matthew B Crisp(Executive Officer, Director)LPLee Palles(Executive Officer)inNadine Carozzi(Executive Officer)Todd C Mockler(Executive Officer)Thomas Brutnell(Executive Officer)

BoardDaniel J Broderick(Director)

Co-investorsACActivant CapitalBIBioGenerator VenturesCUCultivation CapitalFAFall Line CapitalGVGV (Google Ventures)ISiSelect Fund+7 more

Bright Peak Therapeutics is a biotechnology company developing multi-functional PD-1 inhibitors for cancer immunotherapy, based on its EDC protein-engineering platform.

BiotechHealthtechSan Diego, US

VPVijaya Pattabiraman(Co-founder & Chief Technology Officer)inJBJeffrey Bode(Scientific co-founder)inFWFredrik Wiklund(Chief Executive Officer)Christine Siu(Director)Michael Rosenzweig(Director)Bertolt Kreft(Executive Officer)

Co-investorsRARA CapitalJOJohnson & Johnson Innovation – JJDCVEVersant VenturesVEVenrockBLBlackRockFIFidelity Investments+2 more

AbbVie is a biopharmaceutical company that discovers and delivers medicines for immune-mediated diseases and other therapeutic areas globally.

BiotechHealthtechMedical DevicesSan Diego, US

ABAdrian Bot(Executive Officer)LSLaura Shawver(Executive Officer, Director)inRFRamin Farzaneh-Far(Executive Officer)inJustin Thacker(Executive Officer)Karen Smith(Director)Fabio Pucci(Director)

Co-investorsFIFinchley Healthcare VenturesPFPfizer Venture InvestmentsRARA CapitalSOSofinnova VenturesVIVida VenturesFOForbion

Combines single-cell RNA analysis technology from the Broad Institute with AI/ML models and large-scale clinical sample collection for novel drug discovery and precision medicine.

HealthtechCambridge, US

TKTariq Kassum(Executive Officer, Director)inMBMichael Boretti(Executive Officer)inCLChristoph Lengauer(Executive Officer, Director)in

Co-investorsCACatalio Capital Management, LPFAFast Track InitiativeGVGV (Google Ventures)AMAmplitude Venture CapitalCACasdin CapitalTHThird Rock Ventures

Cambridge, MA clinical-stage biotech developing engineered exosome therapeutics; IPO'd on NASDAQ in 2020, later restructured.

BiotechSeattle, US

DWDoug Williams(Executive Officer, Director)in

BoardNANoubar Afeyan(Director)inSteven Gillis(Director)Eric Lander(Director)

Co-investorsARARCH Venture PartnersECEcoR1 CapitalFIFidelity InvestmentsFLFlagship PioneeringQAQatar Investment Authority

Creyon develops cell-specific therapeutics using aptamer-delivered oligonucleotides, engineering aptamers to deliver therapeutic payloads to immune cells and across the blood-brain barrier for immune-driven and CNS diseases, plus a splice-switching oligonucleotide program for late-onset Pompe disease.

AI & Machine LearningBiotechDeep Tech

Co-investorsBIBioBritDCDCVC (Data Collective)DCDCVC BioTETenmileCACasdin CapitalLULux Capital

Delphia Therapeutics is a biotechnology company developing cancer medicines based on its activation lethality platform, aiming to create therapies effective on their own while combating resistance to targeted therapies.

BiotechHealthtechCambridge, US

KMKevin Marks(Founder)in

Co-investorsGVGV (Google Ventures)NENextech InvestTATaiho Ventures, LLC

Dewpoint Therapeutics develops condensate-modulating drugs by using an integrated platform that maps, measures, and modulates biomolecular condensates to identify druggable targets and disease mechanisms.

AI & Machine LearningBiotechDeep TechBoston, US

RYRichard Young, Ph.D.(Director)inAHAnthony Hyman, Ph.D.(Director)THTony Hyman(Scientific Co-founder)Rick Young(Scientific Co-founder)Elisabeth Leiderman(Executive Officer)inIsaac Klein, M.D., Ph.D.(Executive Officer)

Co-investorsARARCH Venture PartnersECEcoR1 CapitalGEGeneral CatalystSASamsara BioCapital6 6 Dimensions CapitalINInnovation Endeavors+6 more

Dispatch Bio develops a universal immunotherapy treatment for solid tumors, combining engineered immunotherapy with a tumor-specific virus to improve cancer treatment outcomes.

BiotechDeep TechMedical Devices

LJLex Johnson(Co-Founder and Chief Platform Officer)inRLRay Liu(Co-founder and Head of Synthetic Biology)JMJeff Marrazzo(Founder)inSOSabah Oney(Chief Executive Officer)in

Co-investorsARARCH Venture PartnersSTStanford University

Dren Bio is a clinical-stage biopharmaceutical company developing novel antibody therapeutics designed to selectively eliminate pathogenic cells and disease-causing agents, with a pipeline targeting oncology, autoimmune diseases, immunology, and neurology.

BiotechHealthtechMedical DevicesFoster City, US

NTNenad Tomasevic(Founder)

BoardIvan Trifunovich(Director)John Wesley(Founder)

Co-investors8V8VCAIAisling CapitalHBHBM Healthcare InvestmentsHBHBM PartnersJAJacket River Capital PartnersMIMission Bay Capital+5 more

Dualitas Therapeutics develops bispecific antibody therapies that pair a proprietary proximity engager arm with an antibody against a therapeutic target, using its DualScreen discovery engine to identify synergistic target combinations.

BiotechDeep TechSouth San Francisco, US

Greg Lazar, Ph.D.(Co-Founder and Chief Scientific Officer)FHForbes Huang(Co-Founder, Chief Operating Officer & Chief Business Officer)inGLGreg Lazar(Co-Founder & Chief Scientific Officer)inRichard Murray(Executive Officer, Director)KDKarim Dabbagh(Chief Executive Officer, Board Member)in

BoardALAlicia Levey(Director)

Co-investorsQIQiming Venture PartnersSVSV Health InvestorsVEVersant VenturesDEDementia Discovery FundQIQiming HealthcareQIQiming Venture Partners USA

San Diego protein-sequencing company behind the ProteoCode platform; ceased operations in late 2025.

Co-investorsARARCH Venture PartnersDEDecheng CapitalDEDeerfield Management CompanyGVGV (Google Ventures)NANan Fung Life SciencesNONorthpond Ventures

Ensoma is a genomic medicine company developing a platform for in vivo engineering of hematopoietic stem cells (HSCs), combining an off-the-shelf delivery system with a gene engineering toolkit intended to treat diseases with a one-time treatment.

BiotechHealthtechMedical DevicesBoston, US

Albert Seymour(Director)

BoardKPKush Parmar(Executive Officer, Director)inPSPaula Soteropoulos(Director)SKStephen Knight(Director)in

Co-investors5A5AM VenturesAJAju IB InvestmentCACatalio Capital Management, LPDEDelos CapitalF-F-Prime CapitalSOSolasta Ventures+10 more

BiotechSouth San Francisco, US

Aaron Tynes Hammack(Executive Officer, Director)Nicholas Conley(Executive Officer, Director)

BoardPing-Chuan Tsai(Director)

Co-investorsSTStartXMAMatrix Capital ManagementSVSv Tech Ventures, Inc.VIViking Global Investors

EVELO manufactures premium electric bikes designed for comfort and long-distance riding, sold direct-to-consumer with industry-leading warranty and support.

ConsumerDirect to ConsumerE-commerceHardwareMobility & TransportationSeattle, US

YMYevgeniy Mordkovich(Executive Officer, Director)inBoris Mordkovich

Co-investorsFOForefront VentureFLFlagship PioneeringGVGV (Google Ventures)KAKaiser Permanente Ventures

BiotechCambridge, US

JGJennifer Glennon(Executive Officer)inBalkrishan (Simba) Gill, Ph.D.(Executive Officer, Director)Duncan McHale(Executive Officer)inWDWilliam DeVaul(Executive Officer)inMark Bodmer, Ph.D.(Executive Officer)

BoardNoubar B. Afeyan, Ph.D.(Director)

Co-investorsGVGV (Google Ventures)SVSV Health InvestorsFLFlagship PioneeringKAKaiser Permanente VenturesMAMayo Clinic Ventures

Floot is a no-code AI app builder that enables users without coding knowledge to create fully functional mobile and web applications by describing their requirements.

AI & Machine LearningDeveloper ToolsEnterprise SoftwareSaaSSan Francisco, US

YYYujian Yao(CEO)inELEdward Look(Founder)inFloot Team(Founder)Yujian Yao Edward Look(Founder)

Co-investorsEIEight CapitalPIPioneerY Y Combinator46468 CapitalAMAmino CapitalANAndreessen Horowitz+6 more

Forge Therapeutics operates a drug discovery platform focused on developing medicines that target human metalloenzymes.

BiotechDeep Tech

Co-investorsMCMC Healthcare Ventures

Fountain is a biotech company developing first-in-class therapies for diseases and conditions caused by aging, using in vitro and in vivo screening platforms to identify drug candidates.

BiotechHealthtechLongevitySan Francisco, US

Thomas Rando(Co-founder)Joseph Rodgers(Co-founder)inTCTom Cheung(Co-founder)inTsang(Chief Business Officer)

Co-investorsKHKhosla VenturesNANan Fung Life SciencesR4R42 Group

Genomics company building a multi-ancestry biobank and AI-driven analytics for clinical genetic testing and drug discovery.

HealthtechMiami Lakes, US

CDCarlos D. Bustamante(Executive Officer, Director)inArthur Polk(Executive Officer)Alexander Ioannidis(Director)

BoardWAWale Ayeni(Director)inMohit Kaushal(Director)Nicholas Katsanis(Director)

Co-investorsCECEI VenturesCICitta CapitalF-F-Prime CapitalFOFounder CollectiveFUFunction VenturesHEHelios Digital Ventures+4 more

Gencove provides direct-to-consumer genetic sequencing and polygenic risk scoring for health insights.

BiotechDigital HealthHealthtechNew York, US

Tomaz Berisa(Executive Officer, Director)inJPJoseph Pickrell(Executive Officer, Director)in

BoardSESara Eshelman(Director)in

Co-investorsBRBread And Butter Ventures, LlcSPSpero VenturesVEVersion One VenturesBABalaji SrinivasanBUBurst CapitalRERefactor Capital+1 more

Uses a T-cell antigen discovery platform to develop vaccines for oncology and infectious disease.

BiotechCambridge, US

Narinder Singh(Executive Officer)Derek Meisner(Executive Officer)inMichael Alfieri(Executive Officer)Jessica Flechtner(Executive Officer)Girish Aakalu(Executive Officer)Thomas Davis(Executive Officer)

Co-investorsCYCycad Group LLCLULux CapitalMCMC Healthcare VenturesADAdvent Life SciencesAUAuriga PartnersBIBill & Melinda Gates Foundation+1 more

Georgiamune is a biopharmaceutical company developing targeted immunomodulator drugs that activate or down-modulate immune signaling pathways to treat cancer and autoimmune diseases.

BiotechDeep TechHealthtechGaithersburg, US

SNSamir N. Khleif(Founder & CEO)inRIRamy Ibrahim(Chief Medical and Strategy Officer)inMMMikayel Mkrichyan(Senior Vice President of Science and Discovery)SSSarah Sharman(Vice President of IP Legal Affairs)

BoardSPSean Parker(Director)EVElena Viboch(Director)in

Co-investorsCACatalio Capital Management, LPGEGeneral CatalystHAHAWKTAILLALauder PartnersPRPrevail Venture CapitalCACatalio Capital Management+3 more

HealthtechCambridge, US

CHCOLIN HILL(Executive Officer, Director)inIKIYA KHALIL(Executive Officer)inTNTHOMAS NEYARAPALLY(Executive Officer)MARK POTTLE(Executive Officer)inCMCAROL MCCALL(Executive Officer)inBRUCE CHURCH(Executive Officer)in

Co-investorsAMAmgen VenturesECEcho Health Ventures

Nexoplex Bio develops immunotherapies that target tumor cells through recognition of HLA-peptide complexes using multi-specific antibodies, addressing tumor types including lung, gastric, esophageal, head and neck, cervical cancers, and lung squamous cell carcinoma.

BiotechDeep TechHealthtechSan Carlos, US

Wayne(CEO)Rachel(VP of Operations)

Co-investorsBABay City CapitalGVGV (Google Ventures)LALAVLILilly Asia VenturesFRFrazier Healthcare PartnersTHThe Column Group+1 more

Holobiome discovers and develops therapies derived from the human gut microbiome, working to translate microbiome science into probiotics and targeted treatments for whole-body health.

AI & Machine LearningBiotechHealthtechLongevityBoston, US

PSPhilip Strandwitz(Co-founder & Director, Chief Executive Officer)inKLKim Lewis(Co-founder, Director)MLMike La Fleur(President, Co-founder, Director)MLMichael LaFleur(Executive Officer)

BoardJLJoan LaRovere(Director)inICIain Chessell(Director)

Co-investorsABAble PartnersASAstanor VenturesBABantam GroupDEDeep FutureHEHealthtech CapitalISiSelect Fund+4 more

Clinical-stage genetic medicines company using human-derived AAV vectors and nuclease-free gene editing for rare diseases.

BiotechBedford, US

Siyamak Rasty(Executive Officer)Albert Seymour(Executive Officer)

BoardSteven Gillis(Director)ATArthur Tzianabos(Executive Officer, Director)KPKush Parmar(Director)inRichard Gregory(Director)

Co-investors5A5AM VenturesARARCH Venture PartnersOUOUP (Osage University Partners)DEDeerfield Management CompanyFIFidelity InvestmentsHBHBM Healthcare Investments+5 more

Hoofprint Biome develops probiotics and natural enzymes based on microbiome engineering to reduce methane emissions from cattle while improving animal health and feed yield.

AgTechBiotechClimate TechCary, US

KPKathryn Polkoff(Executive Officer, Director)inScott Collins(Founder)inEvan Savell(COO)in

BoardRBRodolphe Barrangou(Director)in

Co-investorsGOGood Growth CapitalPOPonderosa VenturesSOSOSVINIndieBio

IgGenix is a clinical-stage biotechnology company focused on antibody discovery and development for allergies and immunological diseases.

AI & Machine LearningBiotechHealthtechSouth San Francisco, US

Kari Nadeau(Founder)Bruce Hironaka(Founder)Derek Croote(Founder)Stephen Quake(Founder)

Co-investorsKHKhosla VenturesALAllerfund Ventures, LlcFEFemHealth VenturesGLGlobal BrainMEMedical Incubator Japan K.K.SHShangBay Capital LLC+1 more

ImCheck Therapeutics develops next-generation immunotherapeutic antibodies targeting the butyrophilin (BTN) and BTN-like (BTNL) superfamily of checkpoint molecules for immune system modulation.

BiotechHealthtech

DODaniel Olive(Founder)

Co-investorsAGAgent CapitalANAndera PartnersKUKurma PartnersPFPfizer Venture InvestmentsPUPureos BioventuresBPBpifrance+4 more

Immunai develops AMICA, a data platform for decoding the immune system to accelerate drug discovery and development.

AI & Machine LearningBiotechData & InfrastructureNew York City, US

Luis Voloch(Founder)Noam Solomon(Founder)

Co-investorsCACatalio Capital Management, LPGEGefen CapitalICICON - Israel Collaboration NetworkKOKoch Disruptive TechnologiesMEMeron CapitalPEPerot Jain+3 more

Immusoft develops a cell therapy platform called Immune System Programming (ISP) that engineers a patient's B cells into plasma cells that produce therapeutic proteins after being infused back into the patient.

BiotechDeep TechHealthtechSeattle, US

MSMatthew Scholz(Founder)inSASean Ainsworth(Chief Executive Officer)inRSRobert Sikorski(Chief Medical Officer)RHRob Hayes(Chief Scientific Officer)inSMScott McIvor(Chief Development Officer)Eric Garcia(Executive Officer)in

Co-investorsBIBioRock VenturesBOBoston Harbor AngelsBRBreakout VenturesEQEQx FundINInvariantes FundMIMichigan Capital Network+6 more

insitro is a drug discovery and development company that uses machine learning and cellular data to identify therapeutic insights and accelerate the creation of new medicines.

AI & Machine LearningBiotechSouth San Francisco, US

DKDaphne Koller(Founder)inDVDuane Valz(General Counsel)inMRMary Rozenman(Chief Financial Officer)in

BoardRNRobert Nelsen(Director)VPVijay Pande(Director)in

Co-investorsANAndreessen HorowitzARARCH Venture PartnersDEDeviation CapitalFOForesite CapitalGVGV (Google Ventures)HOHOF Capital+9 more

IpiNovyx Bio is a biotech company developing potent and selective immunoproteasome inhibitors to treat cancer, autoimmune, and inflammatory diseases.

BiotechHealthtechMedical DevicesWest Nyack, US

Gang Lin(Scientific Founder)Carl Nathan(Scientific Founder)Franck Barrat(Scientific Founder)inMarc Appel(Executive Officer, Director)Lutz Giebel(Director)James Graham(Director)

Co-investorsPAPathway Bioventures

Karuna Therapeutics is a Boston neuroscience biopharma behind muscarinic drug KarXT, acquired by Bristol Myers Squibb in 2024.

Co-investorsARARCH Venture PartnersPIPivotal Life SciencesSOSofinnova VenturesPUPureTech HealthWEWellcome Trust

Khartis is a drug discovery company developing oral therapies for patients with immune-mediated and chronic diseases.

BiotechMedical DevicesSan Diego, US

Robert Hoffman(Founder; CEO & Head of Research)Craig Murphy, PhD(Founder; Chief Scientific Officer)Chris LeMasters, MBA(Founder; Executive Board Chairman)

Co-investorsFOForesite CapitalNENextech InvestLILilly Asia VenturesLOLongwood Fund

Kytopen develops non-viral gene delivery technology called Flowfect that combines fluid flow with electric fields to deliver payloads such as mRNA, DNA, and CRISPR Cas9 RNP into cells for high-throughput transfection.

BiotechDeep TechHardwareCambridge, US

CBCullen Buie(Founder; Board Observer)inPGPaulo Garcia(Founder)inMCMichael Chiu(Chief Executive Officer)in

BoardPMPaxton Major(Director)inADAnn DeWitt(Director)inPaul Wotton(Director)

Co-investorsBABantam GroupHOHorizons VenturesMAMassVenturesSESelvedge VentureTBTBD AngelsTETelegraph Hill Partners+2 more

LifeMine is a biopharmaceutical company that uses data science and advanced methods to accelerate drug discovery and develop precision medicines across therapeutic areas.

AI & Machine LearningBiotechDeep TechCambridge, US

GLGregory L. Verdine(Executive Officer, Director)GVGregory Verdine, Ph.D.

BoardHingge Hsu(Executive Officer, Director)Weiqing Zhou(Executive Officer, Director)

Co-investorsARARCH Venture PartnersGVGV (Google Ventures)RARA CapitalAIAisling CapitalBEBezos ExpeditionsBLBlue Pool Capital+7 more

Discovering precision small molecule medicines that harness the power of covalency to transform the treatment of immune diseases.

BiotechCambridge, US

Andre Turenne(Executive Officer, Director)in

BoardJHJason Hafler(Director)inBruce Booth(Director)Daniel Becker(Director)

Co-investorsACAccess BiotechnologyDIDigitalis VenturesSASanofi VenturesACAccess IndustriesATAtlas Venture

The page presents "The Pokies Net," an online casino targeting Australian players with a catalog of over 1,600 pokies, table games, and live dealer titles from providers like NetEnt, Pragmatic Play, and Evolution Gaming.

ConsumerGaming

Co-investorsHAHalf Court VenturesHAHAWKTAILNANat TurnerRERefactor Capital

San Diego clinical-stage biopharma developing non-bile acid FXR agonists for liver and gastrointestinal diseases.

BiotechSan Diego, US

Ronald Evans(Director)Trisha Millican(Executive Officer)Ken Song(Executive Officer, Director)

BoardKBKristina Burow(Director)inRHRichard Heyman(Director)inANAmir Nashat(Director)in

Co-investorsAGage1ECEcoR1 CapitalLALAVLILifeSci Venture PartnersLILilly Asia VenturesNENew Enterprise Associates (NEA)+8 more

miRecule is a biotechnology company developing therapeutics, with programs focused on oncology.

BiotechHealthtechGaithersburg, US

ADAnthony D. Saleh(CEO)inDLDave Lemus(COO/CFO)in

Co-investorsALAlumni VenturesBOBoutique Venture PartnersBRBrown and White VenturesPAPathway BioventuresTATachyon VenturesUNUniversity System of Maryland Momentum Fund

Mnemo Therapeutics is a Paris-based clinical-stage biotech developing cell therapies using its EnfiniT epigenetic antigen discovery platform to target tumor-specific antigens for CAR-T therapies.

Co-investorsSOSofinnova PartnersCACasdin CapitalREREDMILE

Molecular Assemblies uses a Fully Enzymatic Synthesis (FES) technology to produce long, pure, and accurate synthetic DNA oligonucleotides, up to 400 bases, without post-synthesis purification.

BiotechDeep TechNew MaterialsSan Diego, US

J. William Efcavitch, Ph.D.(Treasurer and Chief Scientific Officer)MJMichael J. Kamdar(President, Chief Executive Officer and Secretary)Bill Efcavitch(Founder)Curt Becker(Founder)

BoardDavid Hwang(Director)Larry Stambaugh(Chairman of the Board of Directors)

Co-investors1111.2 CapitalDCDCVC (Data Collective)ISiSelect FundKEKeshif VenturesRIRising TideARArgonautic Ventures+2 more

A drug discovery company staffed by scientists and industry specialists focused on developing pharmaceutical candidates.

Biotech

Timur Yusufzai(Founder)inAPAsit Parikh(Chief Executive Officer)in

Co-investorsLILifeSci Venture PartnersNENextech InvestTHThird Rock VenturesCACasdin CapitalCRCreacion VenturesGOGoldman Sachs+3 more

Mozart Therapeutics develops protein therapeutics focused on immunology and oncology treatments.

BiotechMedical Devices

MDMark Davis(Scientific Co-Founder)K. Christopher Garcia(Scientific Co-Founder)CKCalvin Kuo(Scientific Co-Founder)KFKatie Fanning(President & Chief Executive Officer)in

Co-investorsARARCH Venture PartnersJDJDRF T1D FundMRMRL Ventures FundONOno Venture Investment, Inc.PFPfizer Venture InvestmentsSOSofinnova Partners+7 more

CREATE Medicines develops in vivo CAR immunotherapy using proprietary mRNA-LNP technology to program T cells, NK cells, and myeloid cells directly within the body for cancer, autoimmunity, and fibrosis.

AI & Machine LearningBiotechHealthtechMedical DevicesCambridge, US

DGDaniel Getts, Ph.D.(Chief Executive Officer, Cofounder, Board Director)

Co-investorsARARCH Venture Partners8V8VCHAHatteras Venture PartnersNENewpath Partners

nChroma Bio develops in vivo targeted delivery and genetic engineering technologies for genetic medicine applications.

BiotechDeep TechMedical DevicesBoston, US

LGLuke Gilbert, PhD(Founder)Keith Joung, MD, PhD(Founder)DLDavid Liu, PhD(Founder)ALAngelo Lombardo, PhD(Founder)Luigi Naldini, MD, PhD(Founder)JWJonathan Weissman, PhD

Co-investorsATAtlas VentureNENewpath Partners5A5AM VenturesARARCH Venture PartnersDCDCVC (Data Collective)F-F-Prime Capital+11 more

Neurona Therapeutics is a clinical-stage biotherapeutics company developing allogeneic neural cell therapies to treat chronic disorders of the nervous system.

BiotechDeep TechHealthtechSouth San Francisco, US

CNCory Nicholas(Executive Officer, Director, Promoter)inJSJames Stutz(Chief Financial Officer and Chief Business Officer)inCPCatherine Priest(Chief Development Officer)inGBGautam Banik(Chief Technology Officer)inEduardo Dunayevich(Chief Medical Officer)inArnold Kriegstein(Director)

Co-investorsBEBerkeley FrontierIAIaso VenturesTHThe Column GroupVIViking GlobalYSYsios CapitalFIFidelity Investments+8 more

Nilo Therapeutics develops immunomodulation therapies that target brain-body neural circuits controlling systemic inflammation, aiming to treat autoimmune and inflammatory diseases.

BiotechDeep TechHealthtechNew York, US

JGJeff Goater(Executive Officer, Director)inKim Seth(CEO)in

BoardTKTim Kutzkey(Executive Officer, Director, Promoter)in

Co-investorsDCDCVC (Data Collective)THThe Column GroupDCDCVC BioLULux Capital

South San Francisco biotech engineering commensal gut bacteria into controllable live therapeutics for chronic diseases.

Daly City, US

Weston Whitaker(Executive Officer, Director, Promoter)William DeLoache(Director)Samuel Smits(Director)

BoardElizabeth Stanley(Director)

Co-investorsALAlta PartnersCECerity Partners VenturesCOColorcon Ventures5A5AM VenturesDCDCVC (Data Collective)DCDCVC Bio+2 more

Nuvig Therapeutics is a biotech company developing immune-modulating therapies for autoimmune and chronic inflammatory diseases, using an endogenous regulatory mechanism intended to treat inflammation without compromising broader immune function.

BiotechLongevity

Co-investorsSASanofi VenturesABabrdn plcB B CapitalDIDigitalis VenturesGLGlobal BioAccess FundLELeaps by Bayer+4 more

Clinical-stage immuno-oncology company developing antibodies derived from the immune systems of 'Elite' cancer responders.

BiotechHouston, US

ABAlice Bexon(Executive Officer)inCJClifford J. Stocks(Director, Executive Officer)inKDKamal D. Puri(Executive Officer)inCRChris Russell(Executive Officer)inRuss Hawkinson(Executive Officer)

BoardSGSteven Gillis(Director)in

Co-investors3B3B Future Health FundCACanaan PartnersGRGreatPoint VenturesRIRiverVest Venture PartnersARARCH Venture PartnersBEBering Capital+5 more

A pharmaceutical company developing therapeutics across oncology, hematology, neuroscience, immunology, and cardiovascular disease with a pipeline of 50 compounds targeting 40+ disease areas.

BiotechHealthtechMedical Devices

Co-investorsANAndreessen HorowitzARARCH Venture PartnersIGiGlobe PartnersAGAgent CapitalCACasdin CapitalHEHeritage Medical Systems+5 more

Outpace Bio develops engineered protein technologies and cell therapies to treat solid tumors, focusing on protein design and T cell engineering to improve cancer treatment efficacy and safety.

BiotechDeep TechMedical DevicesSeattle, US

MLMarc Lajoie(Founder)inSBScott Boyken(Founder)inStanley Riddell(Co-Founder and Scientific Advisor)AFAaron Foster(Executive Officer)inCharity Scripture(Executive Officer)inESEric Soller(Executive Officer)in

Co-investorsARArtis VenturesRARA CapitalABAbstract VenturesATATEL VenturesATAtinum Investment Co. Ltd.CICivilization Ventures Management, Llc+9 more

Overt Bio develops cell therapies that link genes to immune functions using genome-scale discovery platforms.

AI & Machine LearningBiotechMedical DevicesNew York, US

Dr. Legut(Co-Founder and CEO)Dr. Sanjana(Co-Founder)Mateusz Legut(Executive Officer, Director)NSNeville Sanjana(Co-Founder)inMLMat Legut(Co-Founder and CEO)in

BoardVBVasudev Bailey(Director)in

Co-investorsARArtis VenturesCICivilization Ventures Management, LlcFUFusionGAGaingelsHAHAWKTAILWIWing+2 more

Ozette runs a vertically integrated, AI-enabled lab and platform that generates high-dimensional spectral cytometry data and analyzes it to produce reproducible biomarker endpoints for clinical trials.

AI & Machine LearningBiotechHealthtech

GFGreg Finak(Founder)inEGEvan Greene(Founder)inAAAli Ansary(Founder)inRaphael Gottardo(Founder)

Co-investorsALAllen Institute for AI (AI2) IncubatorALAlpha Ascent Ventures LlcM1M12 (Microsoft's Venture Fund)CECercano ManagementMAMadrona Venture GroupOCOCV Partners

Pheast Therapeutics develops immunotherapies targeting cancer, building on foundational research from Stanford's stem cell research institute.

BiotechHealthtechMedical DevicesRedwood City, US

IWIrv Weissman(Cofounder, Scientific Advisor, Board Director)RMRavi Majeti(Cofounder, Scientific Advisor, Board Observer)ABAmira Barkal(Principal Founder, Scientific Advisor, Board Director)inRMRoy Maute(Cofounder & Chief Executive Officer)in

BoardJVJacob Vogelstein(Director)SGSteven Gillis(Director)in

Co-investorsARARCH Venture PartnersCACatalio Capital Management, LPCACatalio Capital Management

Precede Biosciences develops a blood-based diagnostic platform that profiles gene expression from cell-free DNA to reveal disease biology at the transcriptional level for drug developers and clinical trials.

AI & Machine LearningBiotechDigital HealthBoston, US

RVRehan Verjee(Co-Founder, Chief Executive Officer, Board Director)inSBSylvan Baca(Co-Founder; Assistant Professor of Medicine, Dana-Farber Cancer Institute)inTCToni Choueiri(Co-Founder; Director, Lank Center for GU Oncology, Dana-Farber Cancer Institute)Matthew Freedman(Co-Founder; Professor of Medicine, Dana-Farber Cancer Institute)

Co-investors5A5AM VenturesILIllumina VenturesOUOUP (Osage University Partners)LILilly Asia VenturesS2S28 CapitalUPUPMC Enterprises

Prompt is an Ambient AI product and research company that develops human-centered AI products designed to sense the physical environment.

AI & Machine LearningConsumerDeep TechSan Francisco, US

TXTete Xiao(Founder)in

Co-investorsABAbstract VenturesAIAIX VenturesDCDCVC (Data Collective)NENeotribe VenturesBRBraidwellCDCDP Venture Capital+4 more

Proniras Corporation is a clinical-stage biotechnology company developing novel small-molecule therapeutics for substance use disorders and specialty central nervous system (CNS) conditions, including treatments for opioid withdrawal and seizure disorders.

BiotechHealthtechSeattle, US

CTCHRISTOPHER TOOMBS(Executive Officer)inLRLINDSAY RAYLE(Executive Officer, Promoter)M. Johnston Erwin(Director)David Schubert(Executive Officer, Promoter)

BoardSGSTEVEN GILLIS(Director)inThong Le(Executive Officer, Director, Promoter)

Co-investorsACACCELERATOR LIFE SCIENCE PARTNERSARARCH Venture PartnersWRWRF Capital

Proxima develops AI-powered gaming experiences and infrastructure, with a focus on embodied AI agents and applied AI systems for interactive entertainment.

AI & Machine LearningGamingSan Francisco, US

Ran Mo(Founder)in

Co-investorsKOKonvoy VenturesPRProgressionAIAIX VenturesBABalderton CapitalBABayern KapitalBRBraidwell+9 more

Remedy Plan is a biopharmaceutical company developing drugs that target NAMPT, an essential enzyme dysregulated in more than 20 diseases including cancer.

BiotechHealthtechRockville, US

Gregory Plan Crimmins(Executive Officer, Director)

Co-investors2020/20 HealthCare Partners LLCSCSchooner Capital

Remix Therapeutics develops RNA reprogramming technology to treat various diseases and disorders.

AI & Machine LearningBiotechWatertown, US

Peter Smith, PhD(Co-Founder, President and Chief Executive Officer)Peter Smith(Co-Founder, President and Chief Executive Officer)inRGRobert Gagnon(Executive Officer)HWHeather Wasserman(Executive Officer)inMPMatthew Patterson(Director)inSBScott Biller(Director)in

Co-investorsATAtlas VentureFOForesite CapitalTHThe Column GroupARARCH Venture PartnersDEDecheng Capital

Boston-based biotech developing drugs against the 'dark genome'/repeatome for autoimmune disease, cancer and neurodegeneration.

Benjamin Greenbaum(Founder)David Ting(Founder)Rosana Kapeller(Founder)

Co-investorsANAndreessen HorowitzARARCH Venture PartnersGVGV (Google Ventures)LULuma GroupSASanofi VenturesABAbingworth+11 more

Serinus Biosciences uses AI and systems biology to design drug combinations that overcome cancer cells' resistance to existing treatments, targeting safer and more effective therapeutic options.

BiotechHealthtechNew York City, US

AYAdam Yaari(CEO)inMSMaxwell Sherman(CTO)in

Co-investorsILIllumina VenturesMEMetaplanetPIPioneerSASapir Venture PartnersVEVertex Ventures IsraelY Y Combinator+5 more

BiotechDigital HealthMedical DevicesSeattle, US

PAPeter A. Thompson(Executive Officer, Director)in

Co-investorsECEcoR1 CapitalPOPontifax Venture CapitalRARA CapitalUSUS Venture PartnersNENextech InvestOROrbiMed

Sonoma provides a governance platform for enterprise deployments of AI agents built on the Model Context Protocol (MCP), offering a self-service MCP catalog, workflow builder, entitlement policies, audit logging, and security controls such as supply chain scanning and prompt injection protection.

AI & Machine LearningCybersecurityEnterprise Software

SCStephen Cobbe(Founder)in

Co-investorsFRFrazier Life SciencesGOGoAhead VenturesHAHawk Hill Ventures8V8VCARARCH Venture PartnersLILifeforce Capital

SonoThera is developing a nonviral, non-invasive gene delivery technology that uses ultrasound and microbubbles (ultrasound-mediated delivery) to deliver genetic payloads to targeted sites in a redosable way.

BiotechDeep TechDigital HealthHealthtechSouth San Francisco, US

KGKenneth Greenberg(Co-Founder, President & CEO)in

Co-investorsVIVida VenturesLELeaps by BayerARARCH Venture PartnersFOFoothill VenturesILIllumina VenturesMEMedical Excellence Capital+8 more

Syros Pharmaceuticals is a Massachusetts gene-control biotech developing small molecules that regulate disease gene expression.

BiotechCambridge, US

Nancy Simonian(CEO)Peter Wirth(Director)Mark Alles(Director)Philip Sharp(Director)Richard A. Young(Director)Sue Gail Eckhardt(Director)

Co-investorsAIAisling CapitalARARCH Venture PartnersQUQuan CapitalALAlly Bridge GroupBABain CapitalBABain Capital Life Sciences+11 more

Durham, US

Kris Wood(Director)inEoin McDonnell(Executive Officer, Director)in

Co-investorsKDKdT Ventures

Ten63 develops drug-discovery technology that combines generative chemistry with quantum-accurate molecular simulation, including BEYOND (a large quantum chemistry model) and Sentinel (a virtual CSO for target selection), to design therapeutics against previously undruggable targets.

AI & Machine LearningBiotechDeep TechDurham, US

MAMark A. Hallen(Founder & CTO)inMFMarcel Frenkel(Founder & CEO)inDPDamien Petty(Director)inJia Wei Xu(Director)Bruce Donald, PhD(Founder & Chair SAB)

Co-investorsCACape Fear BioCapitalDFDFJ DragonFundDRDraper AssociatesDUDuke Capital PartnersHAHatteras Venture PartnersSOSOSV+4 more

PartnerJoel Marcus· solo GP

Terray is a drug discovery company that combines proprietary hardware, large-scale experimental datasets, and AI through its EMMI platform to design small molecule medicines.

AI & Machine LearningBiotechDeep TechPasadena, US

EBEli Berlin(Founder)inJacob Berlin, Ph.D.(Chief Executive Officer)Jacob Berlin(Founder)Jacob Berlin Eli Berlin(Founder)Nathan Collins(Founder)

BoardCPChris Picardoin

Co-investorsDEDeviation CapitalDIDigitalis VenturesGAGaingelsMAMadrona Venture GroupMAMana VenturesNVNVIDIA+6 more

BiotechCambridge, US

James G. McArthur(Executive Officer)ANAbraham N. Ceesay(Executive Officer)Christoph M. Adams(Executive Officer, Director)

BoardMette Kirstine Agger(Director)David Mott(Director)Sandip Agarwala(Director)

Co-investorsLOLongitude CapitalLULundbeckfonden VenturesNENew Enterprise Associates (NEA)

Transforming the food system using seaweed, a highly sustainable protein source.

Albany, US

BZBeth Zotter(Executive Officer, Director)inASAmanda Stiles(Director)in

Co-investorsCLClear Current CapitalCOCollaborative FundISISVJUJuniperSUSustainable Food VenturesAGAgFunder+2 more

Umoja Biopharma develops in vivo CAR T cell cancer therapies using its VivoVec platform, which generates chimeric antigen receptor T cells directly inside a patient's body rather than through the traditional ex vivo process.

BiotechHealthtechSeattle, US

AMAndrew M. Scharenberg(Executive Officer, Director)Philip S. Low(Director)Andrew Scharenberg(Founder)Michael Jensen(Founder)Philip Low(Founder)Ryan Crisman(Founder)

Co-investorsMPMPM BioImpactDCDCVC BioQIQiming Venture Partners USASOSoftBank GroupK2K2 HealthVenturesSOSoftBank Vision Fund+2 more

Valora Therapeutics is a biotech company developing antibody-lectin chimera (AbLec) therapeutics that target cell-surface glycans for immuno-oncology and immunotherapy applications.

BiotechHealthtechLa Jolla, US

MGMiguel Garcia-Guzman(Co-Founder, CEO & Director)inCBCarolyn Bertozzi(Scientific Co-Founder)JSJessica Stark(Scientific Co-Founder)inJLJames Lee(VP, Business Development)in

BoardStefan Heller(Director)SMSanford Madigan(Director)in

Co-investorsAVAvalon BioVenturesCOCorrelation Ventures

Ventus AI is an enterprise automation platform offering AI agents ("AI teammates") that operate inside existing systems—desktop apps, web portals, and legacy software—without API integrations to automate complex business workflows, handling MFA, CAPTCHAs, and phone calls.

AI & Machine LearningEnterprise SoftwareHealthtechCasa Grande, US

Maran Vedamanikam(CEO and Manager)Peter Qian(Co-founder & CEO)Vincent Lu(Co-founder & CTO)

Co-investorsSASamsung NextANAndreessen HorowitzWNWndrCoBIBiotechnology Value FundCACasdin CapitalFOFonds de solidarité FTQ+5 more

Ventus discovers and develops small-molecule medicines using its proprietary ReSOLVE platform, focused on structure-based drug discovery.

AI & Machine LearningBiotechDeep TechHealthtechWaltham, US

Judith Lieberman(Co-Founder)DKDaniel Koerwer(Executive Officer)inMCMichael Crackower(Executive Officer)inZachary McNealy(Executive Officer)Marcelo Bigal, M.D., Ph.D.(President and Chief Executive Officer)

BoardJRJosh Resnick(Director)in

Co-investorsANAndreessen HorowitzGVGV (Google Ventures)RARA CapitalSOSoftBank Vision FundVEVersant VenturesBIBiotechnology Value Fund+3 more

Developing novel treatments based on the 12-LOX pathway for immuno-inflammatory diseases.

Co-investorsALAlumni VenturesHAHatteras Venture PartnersPAPappas CapitalSASanofi VenturesGEGenesys CapitalJDJDRF T1D Fund+4 more

Vividion Therapeutics develops small molecule therapeutics using a covalent-first chemoproteomics approach to identify and target previously undruggable proteins.

AI & Machine LearningBiotechDeep TechPrinceton, US

BCBen Cravatt(Scientific Founder)PBPhil Baran(Scientific Founder)JYJin-Quan Yu(Scientific Founder)Aleksandra Rizo(President and Chief Executive Officer)in

BoardJPJohn Park(Executive Officer)JCJohn Clarke(Executive Officer, Director)in

Co-investorsARARCH Venture PartnersAVAvoro Capital AdvisorsCACardinal PartnersNENextech InvestSOSoftBank Vision FundALALTITUDE LIFE SCIENCE VENTURES+4 more

Neurodegenerative disease drug discovery correcting misfolded-protein cellular pathologies.

ConsumerHealthtechMedia & EntertainmentBoston, US

N. Anthony Coles(Executive Officer, Director)RPRichard Peters(Executive Officer, Director)Paulash Mohsen(Executive Officer)Brigitte Robertson(Executive Officer)RARichard A. Heyman(Director)inJeffery W. Kelly(Director)

Co-investorsALAltium CapitalDODolby Family VenturesPFPfizer Venture InvestmentsSASanofi VenturesFIFidelity InvestmentsREREDMILE

ZymoChem develops bio-based materials using proprietary Carbon Conserving (C2) microbes that convert renewable feedstocks into high-value materials with increased yields.

BiotechCircular EconomyClimate TechNew MaterialsSan Leandro, US

HCHarshal Chokhawala(Chief Executive Officer & Co-Founder)inLindy Fishburne(Director)Phil Grayeski(Director)Taehong Huh(Director)Timothy Dummer(Executive Officer, Director)Jon Kuchenreuther(Co-Founder)

Co-investorsACAccelr8BRBreakout LabsBRBreakout VenturesCACavallo VenturesDUDudley FundFRFreshTracks Capital+8 more